MedTrace Logo

Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

NCT04682249 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-02-04

No results posted yet for this study

Summary

This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(first-line treatment from NCCN guideline), our previous study found similar results from FOLFOX (second-line treatment from NCCN guideline) compared with GEMOX.

Our current study were conducted for further investigation to verify the better method for metastatic ICC.

Conditions

  • ICC

Interventions

DRUG

Systemic Chemotherapy

Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)

DRUG

Sintilimab

Sintilimab

DRUG

Apatinib

Apatinib

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-02-01
Completion
2021-02-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04682249 on ClinicalTrials.gov